Healthcare
VistaGen Therapeutics, Inc.(VTGN)
Live Price
Offline$0.58
+1.75% today
1Y Change
-70.41%
Window
Jun 23, 2025 โ Jun 12, 2026
- Market Cap
- $20.00M
- Revenue Growth
- -54.3%
- EPS Growth
- -9.9%
- Dividend Yield
- 0.0%
Coverage: 245 bars ยท Jun 23, 2025 โ Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
VistaGen Therapeutics, Inc. (VTGN) is a Healthcare stock with a market cap of $20.00M and listed on NASDAQ. The stock last traded around $0.58 and down 70.4% across the available one-year price window (Jun 23, 2025 โ Jun 12, 2026). Baseline metrics include revenue growth of -54.3%, EPS growth of -9.9%, a dividend yield of 0.0%. What stands out right now is revenue -54.3%, EPS -9.9%, free cash flow -63.4% with operating margin -8847.8% and ROIC -133.1%. Valuation already assumes a fairly strong business story at price/sales 25.8. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines VTGN price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-54.3% vs +7.6% peer median
Operating Margin
Below sector median
-8847.8% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Jun 16, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -54.3% and EPS is at -9.9%, with operating margin around -8847.8%.
The next real check-in already has a date
The next earnings event is scheduled for Jul 1, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +9.1% over the next 5 trading days and finished higher after 3 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Feb 12, 2026 | +11.8% | -7.3% | +1.8% | +10.9% |
2025 Nov 13, 2025 | -5.9% | +0.0% | +17.1% | +11.8% |
2025 Aug 7, 2025 | +0.0% | +8.8% | +8.4% | +30.0% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
VTGN
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
VTGN Max Drawdown
-89.59%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for VTGN and SPY.
Company Overview
VistaGen Therapeutics, Inc.
NASDAQ Capital Market
VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in Phase III development for the acute treatment of anxiety in adults with social anxiety disorder. Its PH94B product candidature also has potential to treat a range of anxiety disorders, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder, preprocedural anxiety, and panic disorders. The company's CNS pipeline also comprises PH10, a rapid-onset neuroactive nasal spray, which is in preparation for Phase 2B clinical development as a stand-alone treatment for major depressive disorder (MDD); and AV-101, an oral N-methyl-D-aspartate receptor antagonist, which is in development in combination with oral probenecid as a potential treatment of levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation. It has contract research and development agreement with Cato Research Ltd.; license agreement with Pherin Pharmaceuticals, Inc.; and license and collaboration agreement with EverInsight Therapeutics Inc. VistaGen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California.
- Leadership
- Shawn K. Singh
- IPO Date
- Jun 21, 2011
- Employees
- 48
- Street Address
- 343 Allerton Avenue
- Mailing
- South San Francisco, CA, 94080
- Region
- South San Francisco, CA, US
- Reporting Currency
- USD
- Investor Line
- 650 577 3600
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- 0.4
- Price/Sales
- 25.8
- Price/Book
- 0.5
Growth
- Revenue
- -54.3%
- EPS
- -9.9%
- Free Cash Flow
- -63.4%
Profitability
- Gross Margin
- 54.7%
- Operating Margin
- -8847.8%
- Net Margin
- -8486.8%
- ROE
- -109.7%
- ROIC
- -133.1%
Balance Sheet
- Debt/Equity
- 0.03
- Current Ratio
- 4.67
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.